Boston Scientific Corp (BSX) Secures FDA Labeling Expansion for FARAPULSE Pulsed Field Ablation (PFA) System

Boston Scientific Corporation (NYSE:BSX) is one of Goldman Sachs’ top healthcare stock picks. On July 7, Boston Scientific (NYSE:BSX) saw its shares rise as TD Cowen reaffirmed its Buy rating and $115 price target following FDA approval to expand the use of its Farapulse system for treating persistent atrial fibrillation (AFib).

Boston Scientific Corp (BSX) Secures FDA Labeling Expansion for FARAPULSE Pulsed Field Ablation (PFA) System

Image: Courtesy of Boston Scientific

Previously approved for paroxysmal AFib, the system showed strong safety and efficacy results in clinical trials, with no strokes and over 85% of patients free from arrhythmia recurrence after one year.

The company sees significant growth potential in persistent AFib, which accounts for 25–50% of cases and anticipates further regulatory approvals in Europe, Japan, and China. Boston Scientific is also advancing new clinical research with the ReMatch trial, highlighting its continued innovation in cardiac care solutions.

Boston Scientific Corporation (NYSE:BSX) is a medical technology company that develops, manufactures, and markets medical devices. Its products are used in various interventional medical specialties to improve patient outcomes and address unmet needs.

While we acknowledge the potential of BSX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BSX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 11 Best Green Energy Penny Stocks to Buy Right Now and 10 Most Popular AI Penny Stocks to Buy According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.